SMAD3 and neoplasm: We found that genetic deletion or pharmacological inhibition of Smad3 significantly enhanced the production of NK cells (NK1.1+/NKp46+ cells) locally in the tumour microenvironment and systemically in the peripheral blood and splenic tissue.